Brief: Seikagaku signs exclusive worldwide license agreement for treatment for lumbar disc herniation
29/08/2016 08:16
Aug 29 (Reuters) - Seikagaku Corporation 4548.T :
* Says the co entered into an exclusive worldwide license
agreement(excluding Japan) with Ferring Pharmaceuticals for
SI-6603(condoliase), a potential treatment for lumbar disc
herniation
* Says the co will receive an upfront payment of $5 million
and milestone payments up to a maximum total amount of $90
million over multiple years upon future progress in development
and commercialization
Source text in Japanese:https://goo.gl/9ApDoi
Further company coverage: 4548.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: jun.cao.reuters.com@reuters.net))